Publications by authors named "Bootsakorn Loharjun"
Background: The durability of heterologous COVID-19 vaccine effectiveness (VE) has been primarily studied in high-income countries, while evaluation of heterologous vaccine policies in low- and middle-income countries remains limited.
Objective: We aimed to evaluate the duration during which the VE of heterologous COVID-19 vaccine regimens in mitigating serious outcomes, specifically severe COVID-19 and death following hospitalization with COVID-19, remains over 50%.
Methods: We formed a dynamic cohort by linking records of Thai citizens aged ≥18 years from citizen vital, COVID-19 vaccine, and COVID-19 cases registry databases between May 2021 and July 2022.
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
William H K Schilling Podjanee Jittamala James A Watson Simon Boyd Viravarn Luvira Bootsakorn Loharjun
Lancet Infect Dis
January 2024
Article Synopsis
- - The ongoing PLATCOV trial compares the antiviral effects of molnupiravir and ritonavir-boosted nirmatrelvir in treating early symptomatic COVID-19 patients across various countries including Thailand and Brazil, using viral clearance as the main measure of effectiveness.
- - In this phase 2, open-label trial, low-risk adults aged 18-50 with COVID-19 symptoms were randomly assigned to one of seven treatment groups, including both antiviral drugs and a no-drug control group, ensuring at least 20% of participants received no medication.
- - The study assesses the rate of viral clearance and treatment safety over one week using a Bayesian model to evaluate the effectiveness of the antiviral treatments, aiming to establish if either